Sandoz enters into commercialization and supply agreement for insulin biosimilars
HOLZKIRCHEN, Germany — Sandoz, a Novartis division and the pioneer and global leader in biosimilars, today announced that it has entered into an agreement to commercialize biosimilar versions of insulins used in patients with type 1 and type 2 diabetes. These medicines are currently in early and clinical stages of development for the European Union (E.U.),
